Carregant...
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA‐Mutated HR+/HER2– Advanced Breast Cancer
Treatment with alpelisib and letrozole appears to be effective in patients with HR‐positive, HER2‐negative, PIK3CA‐mutated advanced breast cancer previously treated with a CDK 4/6 inhibitor, according to updated findings from the phase II BYLieve trial.
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869319/ https://ncbi.nlm.nih.gov/pubmed/33399247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13662 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|